In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can ...

That treatment, called CAR-T therapy, had been a groundbreaking step forward for cancer patients.

Personalized therapies for diabetes, while showing promise in international studies, is met with healthy skepticism from ...

Readers will learn how veterinary oncologists stage and treat canine lymphoma using modern multi-agent chemotherapy and palliative care.

Wistar Institute scientists have designed a two-vaccine approach that not only targets the tumors’ unique molecular identity ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can “educate” the immune system to find and destroy disease-causing cells throughout ...

Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal ...

The breakthrough, published Tuesday in the journal Cell, offers a promising new strategy to combat relapse, which occurs in ...